Cargando…
P1532: SUTIMLIMAB AFTER PRIOR RITUXIMAB USE IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): POOLED POST-HOC ANALYSES FROM THE CARDINAL AND CADENZA TRIALS
Autores principales: | Röth, A., Karaouni, A., Msihid, J., Hemim, I., Joly, F., Shafer, F., Sourdille, T., Hill, Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430638/ http://dx.doi.org/10.1097/01.HS9.0000848984.06528.b5 |
Ejemplares similares
-
P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
por: Barcellini, Wilma, et al.
Publicado: (2023) -
Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies
por: Fattizzo, Bruno, et al.
Publicado: (2022) -
P1487: CONCOMITANT USE OF SUTIMLIMAB AND COVID-19 VACCINES IN PATIENTS WITH COLD AGGLUTININ DISEASE FROM THE PHASE 3 CARDINAL AND CADENZA STUDIES
por: Fattizzo, Bruno, et al.
Publicado: (2023) -
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022) -
P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396)
por: Röth, A., et al.
Publicado: (2022)